<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://genmapp.org/GPML/2010a" Name="Platelet activation triggers" Organism="Homo sapiens" Data-Source="Reactome - http://www.reactome.org" Version="release 35">
  <Comment Source="WikiPathways-description">In the initial response to injury, platelets adhere to damaged blood vessels, responding to the exposure of collagen from the vascular epithelium. Once adhered they degranulate, releasing stored secondary agents such as ADP and ATP, and synthesized thromboxane A2. These amplify the response, activating and recruiting further platelets to the area and promoting platelet aggregation. Adenosine nucleotides secreted following platelet activation signal through P2 purinergic receptors on the platelet membrane. ADP activates P2Y1 and P2Y12 while ATP activates the ionotropic P2X1 receptor (Kunapuli et al. 2003). Activation of these receptors initiates a complex signaling cascade that ultimately results in platelet activation and thrombus formation (Kahner et al. 2006). ADP stimulation of P2Y1 and P2Y12 involves signaling via both the alpha and gamma:beta components of the heterotrimeric G-protein (Hirsch et al. 2001, 2006).</Comment>
  <Comment Source="WikiPathways-category">Cellular Process</Comment>
  <DataNode GraphId="n1_REACTOME_392518" TextLabel="Signal amplification&#10;" Type="Pathway">
    <Comment Source="WikiPathways-description">In the initial response to injury, platelets adhere to damaged blood vessels, responding to the exposure of collagen from the vascular epithelium. Once adhered they degranulate, releasing stored secondary agents such as ADP and ATP, and synthesized thromboxane A2. These amplify the response, activating and recruiting further platelets to the area and promoting platelet aggregation. Adenosine nucleotides secreted following platelet activation signal through P2 purinergic receptors on the platelet membrane. ADP activates P2Y1 and P2Y12 while ATP activates the ionotropic P2X1 receptor (Kunapuli et al. 2003). Activation of these receptors initiates a complex signaling cascade that ultimately results in platelet activation and thrombus formation (Kahner et al. 2006). ADP stimulation of P2Y1 and P2Y12 involves signaling via both the alpha and gamma:beta components of the heterotrimeric G-protein (Hirsch et al. 2001, 2006).</Comment>
    <BiopaxRef>lit_430225</BiopaxRef>
    <Graphics Color="000000" CenterX="531.0" CenterY="264.5" Width="124.0" Height="31.0" Valign="Middle" FillColor="ccffcc"/>
    <Xref Database="Reactome" ID="REACT_20524"/>
  </DataNode>
  <DataNode GraphId="n2_REACTOME_114604" TextLabel="GPVI-mediated &#10;activation cascade&#10;" Type="Pathway">
    <Comment Source="WikiPathways-description">The GPVI receptor is a complex of the GPVI protein with Fc epsilon R1 gamma (FcR). The Src family kinases Fyn and Lyn constitutively associate with the GPVI-FcR complex in platelets and initiate platelet activation through phosphorylation of the immunoreceptor tyrosine-based activation motif (ITAM) in the FcR gamma chain, leading to binding and activation of the tyrosine kinase Syk. Downstream of Syk, a series of adapter molecules and effectors lead to platelet activation. &lt;br&gt;&lt;br&gt;The GPVI receptor signaling cascade is similar to that of T- and B-cell immune receptors, involving the formation of a signalosome composed of adapter and effector proteins. At the core of the T-cell receptor signalosome is the transmembrane adapter LAT and two cytosolic adapters SLP-76 and Gads. While LAT is essential for signalling to PLCgamma1 downstream of the T-cell receptor, the absence of LAT in platelets only impairs the activation of PLCgamma2, the response to collagen and GPVI receptor ligands remains sufficient to elicit a full aggregation response. In contrast, GPVI signalling is almost entirely abolished in the absence of SLP-76.</Comment>
    <BiopaxRef>lit_210193</BiopaxRef>
    <BiopaxRef>lit_210067</BiopaxRef>
    <Graphics Color="000000" CenterX="671.5" CenterY="264.0" Width="117.0" Height="46.0" Valign="Middle" FillColor="ccffcc"/>
    <Xref Database="Reactome" ID="REACT_1695"/>
  </DataNode>
  <DataNode GraphId="n3_REACTOME_456926" TextLabel="Thrombin signalling &#10;through proteinase &#10;activated receptors &#10;(PARs)&#10;" Type="Pathway">
    <Comment Source="WikiPathways-description">Thrombin activates proteinase activated receptors (PARs) that signal through heterotrimeric G proteins of the G12/13 and Gq families, thereby connecting to a host of intracellular signaling pathways. Thrombin activates PARs by cleaving an N-terminal peptide that then binds to the body of the receptor to effect transmembrane signaling. Intermolecular ligation of one PAR molecule by another can occur but is less efficient than self-ligation. A synthetic peptide of sequence SFLLRN, the first six amino acids of the new N-terminus generated when thrombin cleaves PAR1, can activate PAR1 independent of protease and receptor cleavage. PARs are key to platelet activation. Four PARs have been identified, of which PARs 1 ,3 and 4 are substrates for thrombin. In humans PAR 1 is the predominant thrombin receptor followed by PAR4 which is less responsive to thrombin. PAR 3 is not considered important for human platelet responses as it is minimally expressed, though this is not the case for mouse. PAR2 is not expressed in platelets. In mouse platelets, Gq is necessary for platelet secretion and aggregation in response to thrombin but is not necessary for thrombin-triggered shape change. G13 appears to contribute to platelet aggregation as well as shape change in response to low concentrations of thrombin but to be unnecessary at higher agonist concentrations; G12 appears to be dispensable for thrombin signaling in platelets. G alpha (q) activates phospholipase C beta thereby triggering phosphoinositide hydrolysis, calcium mobilization and protein kinase C activation. This provides a path to calcium-regulated kinases and phosphatases, GEFs, MAP kinase cassettes and other proteins that mediate cellular responses ranging from granule secretion, integrin activation, and aggregation in platelets. Gbeta:gamma subunits can activate phosphoinositide-3 kinase and other lipid modifying enzymes, protein kinases, and channels. PAR1 activation indirectly leads to activation of cell surface 'sheddases' that liberate ligands for receptor tyrosine kinases, providing a link between thrombin and receptor tyrosine kinases involved in cell growth and differentiation. The pleiotrophic effects of PAR activation are consistent with many of thrombin's diverse actions on cells.</Comment>
    <BiopaxRef>lit_140168</BiopaxRef>
    <Graphics Color="000000" CenterX="855.5" CenterY="326.0" Width="129.0" Height="76.0" Valign="Middle" FillColor="ccffcc"/>
    <Xref Database="Reactome" ID="REACT_21384"/>
  </DataNode>
  <DataNode GraphId="n4_REACTOME_430116" TextLabel="GP1b-IX-V activation &#10;signalling&#10;" Type="Pathway">
    <Comment Source="WikiPathways-description">The platelet GPIb complex (GP1b-IX-V) together with GPVI are primarily responsible for regulating the initial adhesion of platelets to the damaged blood vessel and platelet activation. The importance of GPIb is demonstrated by the bleeding problems in patients with Bernard-Soulier syndrome where this receptor is either absent or defective. GP1b-IX-V binds von Willebrand Factor (vWF) to resting platelets, particularly under conditions of high shear stress. This transient interaction is the first stage of the vascular repair process. Activation of GP1b-IX-V on exposure of the fibrous matrix following atherosclerotic plaque rupture, or in occluded arteries, is a major contributory factor leading to thrombus formation leading to heart attack or stroke.
GpIb also binds thrombin (Yamamoto et al. 1986), at a site distinct from the site of vWF binding, acting as a docking site for thrombin which then activates Proteinase Activated Receptors leading to enhanced platelet activation (Dormann et al. 2000).</Comment>
    <BiopaxRef>lit_430081</BiopaxRef>
    <BiopaxRef>lit_870285</BiopaxRef>
    <Graphics Color="000000" CenterX="877.5" CenterY="443.0" Width="125.0" Height="46.0" Valign="Middle" FillColor="ccffcc"/>
    <Xref Database="Reactome" ID="REACT_23847"/>
  </DataNode>
  <DataNode GraphId="n6_REACTOME_443917" TextLabel="Thrombopoietin&#10;" Type="Protein">
    <Graphics Color="000000" CenterX="225.0" CenterY="212.0" Width="118.0" Height="38.0" Valign="Middle" FillColor="ccffcc" ShapeType="RoundedRectangle"/>
    <Xref Database="UniProt" ID="P40225"/>
  </DataNode>
  <DataNode GraphId="n7_REACTOME_443938" TextLabel="Thrombopoietin &#10;receptor&#10;" Type="Protein">
    <Graphics Color="000000" CenterX="211.0" CenterY="328.5" Width="104.0" Height="53.0" Valign="Middle" FillColor="ccffcc" ShapeType="RoundedRectangle"/>
    <Xref Database="UniProt" ID="P40238"/>
  </DataNode>
  <DataNode GraphId="n8_REACTOME_443940" TextLabel="TPO:Thrombopoietin &#10;receptor&#10;" Type="Complex">
    <Graphics Color="000000" CenterX="376.5" CenterY="257.5" Width="125.0" Height="53.0" Valign="Middle" FillColor="ccffff" ShapeType="RoundedRectangle" LineThickness="2"/>
    <Xref Database="Reactome" ID="REACT_24575"/>
  </DataNode>
  <Line GraphId="e_5_REACTOME_443926">
    <Comment Source="WikiPathways-description">Thrombopoietin (TPO) is a primary regulator of megakaryocytopoiesis. Binding of TPO to its receptor TPOR (c-Mpl) mediates pleiotropic effects on megakaryocyte development leading to significant increase in circulating platelet numbers. TPOR knockout mice show a marked reduction in bone marrow megakaryocytes and blood platelets. Although thrombopoietin (TPO) by itself has little or no effect on platelet aggregation, pretreatment of platelets with TPO augments the aggregation induced by various agonists such as ADP, thrombin, collagen, and adrenaline.</Comment>
    <Graphics LineStyle="Solid" Color="000000" ConnectorType="Segmented">
      <Point X="250.0" Y="284.0" GraphId="e_5_0"/>
      <Point X="264.0" Y="278.0" GraphId="e_5_1"/>
      <Point X="311.0" Y="268.0" GraphId="e_5_2" GraphRef="n8_REACTOME_443940" RelX="-1.04" RelY="0.41509433962264153" ArrowHead="Arrow"/>
      <Anchor Position="0.0" GraphId="e_5_a_i"/>
      <Anchor Position="0.24068709577746034" GraphId="e_5_a_p"/>
    </Graphics>
  </Line>
  <Line GraphId="e_5_i0">
    <Graphics LineStyle="Solid" Color="000000" ConnectorType="Segmented">
      <Point X="231.0" Y="234.0" GraphId="e_5_i0_0" GraphRef="n6_REACTOME_443917" RelX="0.1016949152542373" RelY="1.1578947368421053"/>
      <Point X="250.0" Y="284.0" GraphId="e_5_i0_1" GraphRef="e_5_a_i"/>
    </Graphics>
  </Line>
  <Line GraphId="e_5_i1">
    <Graphics LineStyle="Solid" Color="000000" ConnectorType="Segmented">
      <Point X="234.0" Y="299.0" GraphId="e_5_i1_0" GraphRef="n7_REACTOME_443938" RelX="0.4423076923076923" RelY="-1.0943396226415094"/>
      <Point X="250.0" Y="284.0" GraphId="e_5_i1_1" GraphRef="e_5_a_i"/>
    </Graphics>
  </Line>
  <Label GraphId="comp_text_9" GroupRef="group_comp_9" TextLabel="cytosol">
    <Graphics Color="000000" CenterX="548.5" CenterY="418.5" Width="59.0" Height="33.0" Valign="Middle" FontSize="12"/>
  </Label>
  <Shape GraphId="comp_9" GroupRef="group_comp_9">
    <Graphics Color="000000" CenterX="548.5" CenterY="374.0" Width="681.0" Height="236.0" Valign="Middle" ShapeType="Rectangle" LineThickness="2.0"/>
  </Shape>
  <InfoBox CenterX="3872.5" CenterY="6350.0"/>
  <Biopax>
    <bp:publicationXref xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" rdf:ID="lit_430225" rdf:id="lit_430225">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">18077812</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pubmed</bp:DB>
      <bp:YEAR rdf:datatype="http://www.w3.org/2001/XMLSchema#int">2007</bp:YEAR>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Platelet activation and atherothrombosis</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">DavÃ¬, G</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Patrono, C</bp:AUTHORS>
      <bp:SOURCE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">N Engl J Med 357:2482-94</bp:SOURCE>
    </bp:publicationXref>
    <bp:publicationXref xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" rdf:ID="lit_210193" rdf:id="lit_210193">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11943772</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pubmed</bp:DB>
      <bp:YEAR rdf:datatype="http://www.w3.org/2001/XMLSchema#int">2002</bp:YEAR>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Suzuki-Inoue, K</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tulasne, D</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Shen, Y</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bori-Sanz, T</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Inoue, O</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Jung, SM</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Moroi, M</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Andrews, RK</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Berndt, MC</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Watson, SP</bp:AUTHORS>
      <bp:SOURCE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">J Biol Chem 277:21561-6</bp:SOURCE>
    </bp:publicationXref>
    <bp:publicationXref xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" rdf:ID="lit_210067" rdf:id="lit_210067">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16102042</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pubmed</bp:DB>
      <bp:YEAR rdf:datatype="http://www.w3.org/2001/XMLSchema#int">2005</bp:YEAR>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">GPVI and integrin alphaIIb beta3 signaling in platelets</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Watson, SP</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Auger, JM</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">McCarty, OJ</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pearce, AC</bp:AUTHORS>
      <bp:SOURCE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">J Thromb Haemost 3:1752-62</bp:SOURCE>
    </bp:publicationXref>
    <bp:publicationXref xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" rdf:ID="lit_140168" rdf:id="lit_140168">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11001069</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pubmed</bp:DB>
      <bp:YEAR rdf:datatype="http://www.w3.org/2001/XMLSchema#int">2000</bp:YEAR>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Thrombin signalling and protease-activated receptors</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Coughlin, SR</bp:AUTHORS>
      <bp:SOURCE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nature 407:258-64</bp:SOURCE>
    </bp:publicationXref>
    <bp:publicationXref xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" rdf:ID="lit_430081" rdf:id="lit_430081">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">15507277</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pubmed</bp:DB>
      <bp:YEAR rdf:datatype="http://www.w3.org/2001/XMLSchema#int">2004</bp:YEAR>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Platelet physiology and thrombosis</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Andrews, RK</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Berndt, MC</bp:AUTHORS>
      <bp:SOURCE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Thromb Res 114:447-53</bp:SOURCE>
    </bp:publicationXref>
    <bp:publicationXref xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" rdf:ID="lit_870285" rdf:id="lit_870285">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17585075</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pubmed</bp:DB>
      <bp:YEAR rdf:datatype="http://www.w3.org/2001/XMLSchema#int">2007</bp:YEAR>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Adhesion mechanisms in platelet function</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ruggeri, ZM</bp:AUTHORS>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mendolicchio, GL</bp:AUTHORS>
      <bp:SOURCE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Circ Res 100:1673-85</bp:SOURCE>
    </bp:publicationXref>
  </Biopax>
</Pathway>